End-of-day quote
Korea S.E.
06:00:00 2024-06-18 pm EDT
|
5-day change
|
1st Jan Change
|
3,995
KRW
|
-2.92%
|
|
-7.09%
|
-21.67%
|
Fiscal Period: December |
2022
|
2023
|
---|
Capitalization
1 |
149,031
|
98,104
|
Enterprise Value (EV)
1 |
139,324
|
92,073
|
P/E ratio
|
-142
x
|
-22.9
x
|
Yield
|
-
|
-
|
Capitalization / Revenue
|
3.44
x
|
3.04
x
|
EV / Revenue
|
3.21
x
|
2.85
x
|
EV / EBITDA
|
58.7
x
|
218
x
|
EV / FCF
|
-
|
-28,999,508
x
|
FCF Yield
|
-
|
-0%
|
Price to Book
|
3.27
x
|
3.04
x
|
Nbr of stocks (in thousands)
|
19,205
|
19,236
|
Reference price
2 |
7,760
|
5,100
|
Announcement Date
|
3/21/24
|
3/21/24
|
Fiscal Period: December |
2022
|
2023
|
---|
Net sales
1 |
43,374
|
32,275
|
EBITDA
1 |
2,372
|
422
|
EBIT
1 |
-1,475
|
-3,553
|
Operating Margin
|
-3.4%
|
-11.01%
|
Earnings before Tax (EBT)
1 |
-1,042
|
-4,384
|
Net income
1 |
-1,048
|
-4,288
|
Net margin
|
-2.42%
|
-13.29%
|
EPS
2 |
-54.72
|
-223.1
|
Free Cash Flow
|
-
|
-3,175
|
FCF margin
|
-
|
-9.84%
|
FCF Conversion (EBITDA)
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
3/21/24
|
3/21/24
|
Fiscal Period: December |
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
Net Cash position
1 |
9,707
|
6,031
|
Leverage (Debt/EBITDA)
|
-
|
-
|
Free Cash Flow
|
-
|
-3,175
|
ROE (net income / shareholders' equity)
|
-
|
-12.9%
|
ROA (Net income/ Total Assets)
|
-
|
-4.73%
|
Assets
1 |
-
|
90,583
|
Book Value Per Share
2 |
2,370
|
1,675
|
Cash Flow per Share
2 |
988.0
|
157.0
|
Capex
1 |
2,735
|
4,804
|
Capex / Sales
|
6.31%
|
14.89%
|
Announcement Date
|
3/21/24
|
3/21/24
|
|
1st Jan change
|
Capi.
|
---|
| -21.67% | 57.32M | | +34.01% | 51.07B | | +33.84% | 38.86B | | -8.02% | 38.78B | | -8.98% | 26.69B | | +12.56% | 26.35B | | -19.62% | 19.46B | | +39.18% | 13.58B | | +31.47% | 12.46B | | -3.40% | 11.75B |
Other Biotechnology & Medical Research
|